Related Experiment Video
Updated: Jun 27, 2026
Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Translation element EIF4A1 is a potential divergent immune biomarker between colon cancer and rectal cancer
Zhenpeng Zhu1, Peng Wang2, Chenyang Hou1
1Hebei North University, Zhangjiakou City, Hebei Province, China.
Objective:
Given the global high incidence of colorectal cancer (CRC) and the need for subtype-specific molecular targets, this study aims to investigate the role and therapeutic potential of EIF4A1 in colon and rectal cancers.
Introduction:
The potential of Eukaryotic translation initiation factor 4A1(EIF4A1) to guide prognosis and inform immunotherapeutic strategies in colon and rectal cancers warrants further investigation.
Methods:
EIF4A1 expression levels were measured by quantitative real-time PCR (qRT-PCR), and EIF4A1 protein expression was evaluated via immunohistochemistry (IHC). Additionally, multi-dimensional database analyses were performed to characterize the biological functions of EIF4A1 and explore its heterogeneity in CRC.
Results:
EIF4A1 expression was upregulated in both colon and rectal cancers, with significant associations with poor survival outcomes. Functional enrichment analyses indicated that EIF4A1 was predominantly associated with the neutrophil extracellular trap (NET) network in colon cancer. Strong positive correlations between EIF4A1 expression and neutrophil infiltration were observed in both cancer subtypes. Notably, EIF4A1 exhibited divergent immune infiltration patterns: a strong positive correlation with CD8+ T cells in colon cancer, versus a negative correlation with CD4+ T cells in rectal cancer. EIF4A1 also showed strong positive correlations with immune checkpoint molecules (PD-1, PD-L1, CTLA4, and LAG-3) in colon cancer, whereas these correlations were weaker in rectal cancer.
Conclusion:
The heterogeneity of EIF4A1 and its differential roles in driving cancer progression between colon and rectal cancers highlight the need for subtype-specific immunotherapeutic strategies for these malignancies.
Insights
Eukaryotic translation initiation factor 4A1 (EIF4A1) is upregulated in colorectal cancer, correlating with poor survival. Its distinct roles in colon versus rectal cancer suggest tailored immunotherapies are needed.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Colorectal cancer (CRC) has a high global incidence.
- Identifying subtype-specific molecular targets is crucial for effective CRC treatment.
- Eukaryotic translation initiation factor 4A1 (EIF4A1) shows potential for prognostic and immunotherapeutic applications in CRC.
Purpose of the Study:
- To investigate the role of EIF4A1 in colon and rectal cancers.
- To explore the therapeutic potential of targeting EIF4A1 in CRC.
- To understand the differential expression and function of EIF4A1 in CRC subtypes.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) for EIF4A1 mRNA expression.
- Immunohistochemistry (IHC) for EIF4A1 protein levels.
- Multi-dimensional database analyses for biological function and heterogeneity.
Main Results:
- EIF4A1 was upregulated in both colon and rectal cancers, associated with poor survival.
- EIF4A1 correlated with neutrophil extracellular trap (NET) networks and neutrophil infiltration.
- Differential immune infiltration patterns observed: positive with CD8+ T cells in colon cancer, negative with CD4+ T cells in rectal cancer.
- Strong positive correlations with immune checkpoint molecules in colon cancer, weaker in rectal cancer.
Conclusions:
- EIF4A1 exhibits heterogeneity and differential roles in colon versus rectal cancer progression.
- These findings underscore the necessity for subtype-specific immunotherapeutic strategies in CRC.
- Targeting EIF4A1 may offer a novel approach for personalized CRC treatment.
Related Concept Videos
03:18Non-LTR Retrotransposons
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase